TY - JOUR T1 - A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab JF - The Journal of Rheumatology JO - J Rheumatol SP - 1647 LP - 1647 DO - 10.3899/jrheum.190197 VL - 46 IS - 12 AU - STEVEN R. HWANG AU - ADAM P. SAWATSKY Y1 - 2019/12/01 UR - http://www.jrheum.org/content/46/12/1647.abstract N2 - Manifestations of renal disease have been reported to develop after tumor necrosis factor-α (TNF-α) inhibition, and they should be considered as a possible complication as TNF-α inhibitors become more prevalent in the treatment of autoimmune inflammatory diseases. We report a case of minimal change disease (MCD) that developed in a woman receiving the TNF-α inhibitor certolizumab and was resolved with high-dose steroids and discontinuation of TNF-α blockade. Ethics approval was waived by the Mayo Clinic Institutional Review Board; the patient’s written informed consent was obtained.A 49-year-old woman with a background history of rheumatoid arthritis (RA) and Sjögren syndrome presented with a 1-week history of foamy urine, peripheral edema, and 15-kg weight gain. For her RA, she was taking prednisone 5 mg daily and certolizumab 400 mg monthly; the latter had been started 6 months prior to presentation. Physical examination findings demonstrated 2+ pitting edema to the knees … Address correspondence to Dr. S.R. Hwang, Mayo Clinic, 200 1st St. SW, Rochester, Minnesota 55902, USA. E-mail: hwang.steven{at}mayo.edu ER -